Presentations

Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients ≥60 years old Compared to < 60 years old: Results of a Phase 1b Study

A Phase 2 Trial of Voreloxin (Formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer

Ex Vivo Activity of SNS-595 Against Biopsies of Acute Myeloid Leukemia, Triple Negative Breast and Ovarian Cancers Supports Ongoing and Potential Clinical Indications

Sensitivity to SNS-595 is Related to Activation of Double Strand DNA Break Repair Pathways Including Homologous Recombination

SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning

SNS-595: A cancer therapeutic and novel DNA damaging agent

A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer

A Phase 1b Open-Label Study of the Novel DNA Replication Inhibitor SNS-595 in Refractory Acute Leukemia

SNS-595 demonstrates predictable, dose-proportional pharmacokinetics in three Phase 1 clinical studies

SNS-595 potentiates the in vivo anti-tumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts

A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer

SNS-595: Preliminary Results Of Two Phase 2 Second Line Studies In Lung Cancer

Pharmacokinetic/Pharmacodynamic Correlation with Clinical Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute Leukemias Treated with SNS 595

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias

SNS-595 A Novel S-Phase Active Cytotoxic Acts Synergistically With Cytarabine To Reduce Bone Marrow Cellularity And Circulating Neutrophils

SNS-595 demonstrates Clinical Activity and Dose Proportional Pharmacokinetics (PK) in Two Phase 1 Clinical Studies

SNS-595 Has Synergistic Activity In Vitro With DNA Damaging Agents And Antimetabolites

SNS-595, A Novel S-Phase Active Cytotoxic, Exhibits Potent In Vitro And In Vivo Activities, And Has The Potential For Treating Advanced Hematologic Malignancies

A Phase 1 Trial Of Weekly SNS-595 In Patients (PTS) With Refractory Cancer

CYP450 Inhibition, Induction, Metabolism and Routes of Elimination of SNS-595, a Novel Cell Cycle Inhibitor Currently in Phase I Clinical Trials

Results of a Phase I Trial of SNS-595 in Patients with Advanced Solid Malignancies

SNS-595, A Novel Cell Cycle Inhibitor in Phase 1 Clinical Trials, Causes Tumor Regressions, Cell-Cycle Arrest, and Apoptosis in Murine Models of Cancer

The Phase 1 Clinical Compound SNS-595 Acts During S-Phase and Causes a Sustained G2 Arrest

The potent cytotoxic agent SNS-595 causes a rapid onset of apoptosis during the S-phase of the cell cycle

ADMET and pharmacokinetic properties of SPC-595, a novel cell cycle inhibitory antineoplastic agent in non-clinical species

Non-clinical admet, pk, and biological activity of SNS-595, a novel cell cycle inhibitory antineoplastic agent

In vitro and in vivo activity of SPC-595, a novel cell cycle inhibitory cytotoxic in murine syngeneic and human xenograft tumor models

A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9 INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines

Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol

SNS-032 Has Potent Anti-Tumor Activity In Vivo Against Human Lukemia and Multiple Myeloma Xenografts

SNS-032 Exhibits Dose-Dependent Mechanism-Based Inhibition of CDK7 And CDK9 in Peripheral Blood Mononuclear Cells from Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial

SNS-032 is a potent and selective CDK2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226

SNS-032 Is A Potent And Selective Inhibitor Of CDK2, 7 And 9 And Induces Cell Death By Inhibiting Cell Cycle Progression And The Expression Of Antiapoptotic Proteins.

SNS-314, A POTENT INHIBITOR OF AURORA KINASES, HAS PRECLINICAL ANTI-TUMOR ACTIVITY AND INDUCES APOPTOSIS

SNS-314, a selective Aurora kinase inhibitor with potent, preclinical anti-tumor activity shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agents

Nonclinical pharmacokinetics, distribution, and excretion of SNS-314, a novel, selective Aurora kinase inhibitor

SNS-314, A Novel Small-Molecule Aurora Kinase Inhibitor, Induces Cell-Cycle Defects and Potently Suppresses Tumor Growth

SNS-314, A Potent Inhibitor Of Aurora Kinases, Shows Broad Anti-Tumor Activity And Dosing Flexibility In Vivo

Discovery of Novel Modular Kinase Inhibitors